TL;DR
TL;DR
T1 at $6.10 is a real manufacturing ramp attached to a contested credit engine and — after the run's first upward step, a +4.5% two-session recovery off the $5.84 run low — a price that still pre-pays clearly less of the success case than any print at $6.66 and above: the tape sits net −33.6% below the 2026-07-01 anchor (and −42.2% below the 2026-05-29 $10.56) after the −19.7% session of 2026-07-07, a −10.8% 2026-07-16 leg, and a −1.7% 2026-07-17 leg to the $5.84 low, then the +3.3% / +1.2% bounce to $6.10; $5.84 remains the run low on both measures, and the recovery carries no filing or Federal Register hit behind it (the 2026-07-22 refresh moved only market/history — filings.json, companyfacts.json and policy.json are all hash-unchanged, recent index end still 2026-06-29; the two large drops were press-attributed to reported environmental-violation and safety-practice probes, the bounce to stabilization — an uncorroborated "LNG supply contract" snippet is not relied on). The standing verdict's two halves remain separated. Strongest bull point: Q1 2026 net sales of $177.647M ran 3.32× Q1 2025 with gross margin rising 7.36% → 16.37%, on 3.0 GW of 2026 module sales contracted at fixed margins, and the 45X credit engine is booking ($92M accrued YTD Oct-2025 plus $41.425M added in Q1 alone; ~$210M/yr potential). Strongest bear point: T1 and its G1 plant LLC are named respondents in ITC 337-TA-1494 (First Solar's TOPCon patent — a general exclusion order and cease-and-desist orders requested, plus a parallel district-court willful-infringement suit no document in evidence bounds), while ex-45X the Q1 gross margin is −6.95% and the $225.3–250.3M Phase-1 funding gap has no committed financing disclosed through 2026-06-29 (all 40 index entries examined; index refetched 2026-07-22, recent end unchanged). Priced-in break-even (gap-financed EV, 8×, guidance-midpoint success vs comp-compression failure; the 8× anchor has no comp support in evidence, so the priced-in section shows every conclusion at 6/8/10×): $6.10 is justified iff P_exec × $3.300B + (1 − P_exec) × $0.9947B + V(232+policy) ≥ $2.3330B — at V = 0 that requires P_exec ≥ 58.1%, firmer than the run's softest processed reading of 54.9% at the $5.84 low (56.1% at $5.94) but still softer than every print $6.66 and above (64.8% / 95.4% at $6.66 / $9.18); at P_exec = 60%, 70%, 80% and 90% the required V is negative (−$44.9M / −$275.4M / −$505.9M / −$736.5M) — the negative-V frontier sits just above ~58%, so at ~58% execution confidence and above the price clears with zero policy value; at 50% (a coin flip) it requires V ≥ $185.6M ≈ 0.77¢/W durable on the 3.0 GW book (P(2¢/W remedy) ≥ 38.7%) — a level a certain 2¢/W remedy at 8× ($480M) still covers about 2.6× over. At 8× the market underwrites $261.9M–$319.4M of forward EBITDA — below the floor of the company's own $375–450M guidance band on all four denominator treatments, the treatment closest to the band (diluted, gap-financed) now at −74.1%, recovered from −90.2% at the $5.84 low — against FY2025 operating income of −$234.567M; and as first at $5.94 a 6× multiple can justify the price (midpoint P* = 90.4%, not impossible), with three of four treatments now re-entering the band at 6× ($386.3M–$425.9M) while only the primary proceeds-spent basis ($349.2M) stays below floor — a flip up from $5.84, where only two of four re-entered. P is joint (execution AND 45X eligibility), so an adverse FEOC determination removes the success state rather than lowering its odds. Verdict: the Section 232 option is still priced at or below zero (the 2026-05-29..07-21 tape removed $1,245.6M of EV while the statutory window lapsed unresolved — the +4.5% recovery gave back ~$72.6M of the $5.84 low's −$1,318.2M removal, but the net still runs deeper than the −$1,089.2M at $6.66) — and "Phase-1 success substantially pre-paid" remains an inaccurate description of $6.10, firmed off the run low but still clearly sub-band: the price sits below the bull's own $7.29–$11.32 Phase-1-success band floor (percentile −29.5%, recovered from the −36.0% run low), and no denominator resembles the old "pre-paid" reading (the diluted gap-financed midpoint at 67.7%, off 76.7% at $6.66). Firmed off the run's softest processed reading — the first upward step of the run — but still materially softer than every print at $6.66 and above; near-certainty execution pricing has not returned to any cover-count cell, and the repricing cuts both ways (a probe substantiated in a filing impairs the success state itself; an unsubstantiated one may not keep the price here — and the discount has now begun to reverse, the bounce itself press-framed as stabilization, not a fresh catalyst).
Watch next (from the decisive ledger and catalyst calendar):
| Window | Event | If it lands bullish | If it lands bearish |
|---|---|---|---|
| ~2026-08-14 (45-day deadline, computed) | Q2 2026 10-Q — the richest single checkpoint | Sequential sales above $177.647M, ex-45X margin improving, receivable monetizing, FEOC language intact post-1260H | Revenue fade, grants receivable building without cash, or weakened 45X/FEOC language — the keystone cracks |
| Any day (8-K); else Q2 10-Q Legal Proceedings ~2026-08-14 | Acknowledgment of the press-reported probes and/or a filing documenting the recovery — environmental-violation (behind the −19.7% session of 2026-07-07) and safety-practices (behind the −10.8% session of 2026-07-16); the +4.5% two-session bounce to $6.10 and the uncorroborated "LNG supply contract" snippet also have nothing in the record behind them (the 2026-07-22 refresh moved only market/history; filings.json/companyfacts.json/policy.json all hash-unchanged, recent index end still 2026-06-29) | No filing substantiates the probes and the bounce holds — the discount that eased every break-even to a run low may keep reversing, on nothing in the record; an 8-K confirms the LNG contract or another revenue leg | An 8-K or 10-Q confirms a probe — the success state itself is impaired, not just the price; or the recovery fades back toward the $5.84 low with no news |
| Any day (statutory window expired 2026-06-26; 116/26 days past at the 2026-07-22 run date; the catalyst calendar section holds 112/22 at its 2026-07-18 trailing date) | Section 232 outcome via Federal Register publication | Remedy spares cells and taxes competitors' imported inputs — the upside branch is currently free | Derivative scope reaches cells — taxes T1's own imports during the gap year |
| H2 2026; hard checkpoint ~2026-11-16 (Q3 10-Q) | Committed Phase-1 completion financing ($225.3–250.3M gap) | Signed, mostly non-dilutive facility funds the multiple-turn event and settles the EV-basis dispute (rebuttal item K2, adjudicated in the priced-in section) | Equity/convert raise (bear.md priced 25.9M shares at the $9.18 anchor) or continued absence — the Q4 2026 start becomes arithmetic, not execution |
| Any time (8-K feed; Q2 10-Q) | FEOC/45X determination after Trina's 1260H listing (2026-06-08) | Eligibility confirmed or the $77.8M receivable monetized at par — the ~$210M/yr engine stands | Adverse determination removes the success state; ex-45X Q1 gross margin was −6.95% |
| Any day (FR/EDIS; no target date in evidence) | 337-TA-1494 target-date order / initial determination | Termination, immaterial settlement, or no-violation ID kills the bear's patent leg | Exclusion order reaching imported TOPCon cells exposes all of net sales |